You are here:
| Reference : Pharma-clinics. Le medicament du mois. La combinaison fixe dipyridamole--acide acetylsal... |
| Scientific journals : Article | |||
| Human health sciences : Pharmacy, pharmacology & toxicology | |||
| http://hdl.handle.net/2268/12245 | |||
| Pharma-clinics. Le medicament du mois. La combinaison fixe dipyridamole--acide acetylsalicylique (Aggrenox). | |
| French | |
| [fr] Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox) | |
Scheen, André  [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >] | |
| 2000 | |
| Revue Médicale de Liège | |
| Hopital de Baviere | |
| 55 | |
| 10 | |
| 957-9 | |
| 0370-629X | |
| Liège | |
| Belgique | |
| [en] Aspirin/pharmacology/therapeutic use ; Dipyridamole/pharmacology/therapeutic use ; Drug Combinations ; Humans ; Ischemic Attack, Transient/prevention & control ; Platelet Aggregation Inhibitors/pharmacology/therapeutic use ; Primary Prevention ; Stroke/prevention & control ; Treatment Outcome | |
| [en] Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose combination of extended-release dipyridamole (200 mg) and aspirin (25 mg), two antiplatelet agents with different and complementary mechanisms of action. It is recommended, twice daily, in the protection against secondary stroke and transient ischaemic attacks. The placebo-controlled European study ESPS 2 (European Stroke Prevention Study 2) demonstrated that the administration of this combination was twice as effective as either agent alone in the secondary prevention of stroke in patients with prior stroke or transient ischaemic attack. | |
| http://hdl.handle.net/2268/12245 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.
